AbbVie News | finanzen.ch

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Orderbuch			Analysen
Historisch

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Strukturierte Produkte

Aktion

Portfolio

Watchlist

23.06.17	AbbVie Announces Pivotal Phase 2 Trial Evaluating VENCLYXTO™ (venetoclax) in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) with 17p Deletion to be Presented at 22nd European... (PR Newswire)
22.06.17	AbbVie Declares Quarterly Dividend (PR Newswire)
14.06.17	AbbVie Presents Real-World Data Evaluating the Relationship between Participation in a Patient Support Program and Outcomes in Patients with Moderate to Severe Rheumatoid Arthritis (PR Newswire)
12.06.17	AbbVie Announces New Data Evaluating Venetoclax in a Variety of Hematologic Malignancies at the 22nd European Hematology Association Congress (PR Newswire)
08.06.17	ABBV Hits A High Note, AGN Opens Wallet, TEVA's HALO Does An Encore (RTTNews)
05.06.17	New Data Presented at ASCO 2017 Finds IMBRUVICA® (ibrutinib) May Offer a More Targeted Approach to Chronic Lymphocytic Leukemia (CLL) Treatment than Chemotherapy Agent Chlorambucil in... (PR Newswire)
05.06.17	Long-Term IMBRUVICA® (ibrutinib) Efficacy and Safety Data at ASCO 2017 Show Sustained Survival Rates in Up to Four Years in Previously-Treated Chronic Lymphocytic Leukemia/Small Lymphocytic... (PR Newswire)
24.05.17	AbbVie to Present at the Goldman Sachs 38th Annual Global Healthcare Conference (PR Newswire)
19.05.17	AbbVie to Present at the Jefferies 2017 Global Healthcare Conference (PR Newswire)
18.05.17	Gainers & Losers Of May 17: SNDX, PULM, PBYI, CNCE, XLRN... (RTTNews)
17.05.17	AbbVie to Present Latest Clinical Study Results in Hematology and Solid Tumor Research at the 53rd American Society of Clinical Oncology (ASCO) Annual Meeting (PR Newswire)
17.05.17	UPDATE/MÄRKTE USA/Trumps Skandalserie schickt Aktien auf Talfahrt (Dow Jones)
17.05.17	MÄRKTE USA/Trumps Skandalserie schickt Aktien auf Talfahrt (Dow Jones)
17.05.17	AbbVie Presents Pivotal Phase 3 Data on Investigational Treatment Elagolix at the World Congress on Endometriosis (PR Newswire)
15.05.17	Drug Makers Stocks Under Scanner -- Alliqua BioMedical, AbbVie, Johnson & Johnson, and Merck (PR Newswire)
14.05.17	IMBRUVICA® (ibrutinib) Pooled Outcomes Data from Three Phase 3 Studies Suggest Potential Clinical Efficacy in Patients with High-Risk Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (PR Newswire)
09.05.17	AbbVie Announces Positive Phase 2 Study Results for Upadacitinib (ABT-494), an Investigational JAK1-Selective Inhibitor, in Crohn's Disease (PR Newswire)
08.05.17	United Airlines Increases Service Between San Francisco and 18 Destinations (PR Newswire)
05.05.17	AbbVie to Present at the UBS Global Healthcare Conference (PR Newswire)
04.05.17	AbbVie Demonstrates Leadership in Gastroenterology and Hepatology with New Data and Late-Breaking Studies to be Presented at Digestive Disease Week® (PR Newswire)
27.04.17	AbbVie Reports First-Quarter 2017 Financial Results (PR Newswire)
25.04.17	Aquinnah Pharmaceuticals Receives $10 Million Investment from Pfizer and AbbVie to Research Breakthrough Approach to Neurodegenerative Disease (PR Newswire)
21.04.17	AbbVie to Present at the Deutsche Bank 42nd Annual Health Care Conference (PR Newswire)
21.04.17	Eight Weeks of Treatment with AbbVie's Investigational, Pan-Genotypic Regimen of Glecaprevir/Pibrentasvir (G/P) Achieved High SVR(12) Rates in Challenging to Treat Genotype 3 Chronic Hepatitis C (PR Newswire)
20.04.17	AbbVie's Investigational, Pan-Genotypic, Ribavirin-free Regimen of Glecaprevir/Pibrentasvir (G/P) Achieved 99 Percent SVR(12) Rate in Chronic Hepatitis C Patients with Compensated Cirrhosis (PR Newswire)
10.04.17	Drug Makers Stocks on Investors' Radar -- Pfizer, Merck, Johnson & Johnson, and AbbVie (PR Newswire)
10.04.17	AKRX Confirms Acquisition Talks, CBIO Plunges, Be All Ears For GERN (RTTNews)
07.04.17	AbbVie: Data Shows Elagolix Reduces Menstrual Bleeding In Phase 2b Trial (RTTNews)
07.04.17	AbbVie Announces Positive Phase 2b Data Demonstrating Investigational Medicine Elagolix Significantly Reduced Heavy Menstrual Bleeding in Women with Uterine Fibroids (PR Newswire)
06.04.17	AbbVie to Host First-Quarter Earnings Conference Call (PR Newswire)
31.03.17	The Growth of Legal Cannabis Industry Sales (PR Newswire)
30.03.17	U.S. FDA Approves Addition of Moderate to Severe Fingernail Psoriasis Data to AbbVie's HUMIRA® (adalimumab) Prescribing Information (PR Newswire)
28.03.17	AbbVie and M2Gen Announce New Collaboration for the Oncology Research Information Exchange Network® (ORIEN) Avatar Research Program (PR Newswire)
23.03.17	Julianne Hough Empowers Women to "Get in the Know" About Endometriosis (PR Newswire)
14.03.17	AbbVie Granted Priority Review in Japan for its Investigational Regimen of Glecaprevir/Pibrentasvir (G/P) for the Treatment of All Major Genotypes of Chronic Hepatitis C (PR Newswire)
07.03.17	Drug Makers Stocks Under Scanner -- Pfizer, Merck, AbbVie, and Johnson & Johnson (PR Newswire)
01.03.17	AbbVie to Present at the Barclays Global Healthcare Conference (PR Newswire)
27.02.17	AbbVie Receives CHMP Positive Opinion for Eight-Week Treatment Option with VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA® (dasabuvir tablets) for Patients with Genotype 1b Chronic... (PR Newswire)
17.02.17	AbbVie Announces $5 Billion Increase to Stock Repurchase Program (PR Newswire)
16.02.17	AbbVie Declares Quarterly Dividend (PR Newswire)
15.02.17	AbbVie to Present at the Cowen and Company 37th Annual Health Care Conference (PR Newswire)
02.02.17	U.S. FDA Grants Priority Review to AbbVie for its Investigational Regimen of Glecaprevir/Pibrentasvir (G/P) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT1-6) (PR Newswire)
27.01.17	AbbVie Q4 Adj. Profit Tops Estimates; Sees FY17 Adj. EPS In Line (RTTNews)
27.01.17	AbbVie Reports Full-Year and Fourth-Quarter 2016 Financial Results (PR Newswire)
27.01.17	AbbVie Reports Full-Year and Fourth-Quarter 2016 Financial Results (PR Newswire)
26.01.17	ELGX Abuzz, ESPR Ahead Of Schedule, Tough Times For VIVO (RTTNews)
25.01.17	AbbVie Initiates Phase 2 Clinical Trial Programs for ABBV-8E12, an Investigational Anti-Tau Antibody, in Early Alzheimer's Disease and Progressive Supranuclear Palsy (PR Newswire)
24.01.17	AbbVie: EMA Grants Accelerated Assessment For Glecaprevir/Pibrentasvir Regimen (RTTNews)
24.01.17	European Medicines Agency Grants Accelerated Assessment, Validates Marketing Authorization Application for AbbVie's Investigational Regimen of Glecaprevir/Pibrentasvir (G/P) for the Treatment of... (PR Newswire)
20.01.17	ADMP Waiting To See If 3rd Time Is Charm, FDA Nod For SGYP, Be All Ears For OTIC (RTTNews)

Newssuche

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Part Grp Hldg	1’347.50	0.94 %	K V
CieFinRichemont	165.30	0.76 %	K V
Swisscom	515.00	0.49 %	K V
Lonza Grp	565.60	0.43 %	K V
Alcon	78.26	0.36 %	K V
ABB	50.74	-0.47 %	K V
Roche Hldg G	265.60	-0.49 %	K V
Holcim	86.88	-0.62 %	K V
Geberit	502.40	-0.79 %	K V
Sika	224.20	-1.32 %	K V

mehr

15.01.25		Pluszeichen in New York: S&P 500 zum Ende des Mittwochshandels in der Gewinnzone
15.01.25		Börse New York in Grün: S&P 500 legt zu
15.01.25		Freundlicher Handel in New York: So performt der S&P 500 am Mittag
15.01.25		Aufschläge in New York: S&P 500 zum Start stärker
11.11.24		Börse New York in Grün: S&P 500 zum Handelsende freundlich
11.11.24		Optimismus in New York: S&P 500 am Nachmittag mit Kursplus
11.11.24		NYSE-Handel: S&P 500 mittags freundlich
11.11.24		Freundlicher Handel: Börsianer lassen S&P 500 zum Start des Montagshandels steigen